10058-F4: Selective c-Myc-Max Dimerization Inhibitor for Apoptosis Research

Executive Summary: 10058-F4 is a well-characterized, cell-permeable small-molecule that selectively inhibits c-Myc-Max heterodimerization, directly suppressing c-Myc-driven transcriptional programs (Kotian et al., 2024). By blocking c-Myc/Max dimer formation, it prevents DNA binding and downregulates c-Myc target gene expression, including TERT, the catalytic subunit of telomerase (doi:10.1101/2024.09.16.613267). In AML cell lines and prostate cancer xenograft models, 10058-F4 induces apoptosis and inhibits tumor growth in a dose- and time-dependent manner. The compound is chemically defined as (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one, with specific solubility and storage requirements (APExBIO). Its application extends to apoptosis assays, c-Myc pathway research, and telomerase regulation studies, making it a reference reagent for translational oncology and stem cell biology workflows.

Biological Rationale

c-Myc is a master transcription factor that regulates cell proliferation, metabolism, and apoptosis. Its activity depends on heterodimerization with Max, enabling sequence-specific DNA binding and target gene activation. Dysregulated c-Myc function is implicated in many cancers, including acute myeloid leukemia (AML) and prostate cancer. c-Myc directly controls telomerase (TERT) expression, impacting telomere maintenance and stem cell self-renewal (Kotian et al., 2024). Disrupting c-Myc/Max interactions has emerged as a promising therapeutic strategy for selectively targeting oncogenic transcriptional programs while sparing non-malignant cells. 10058-F4 addresses this need by specifically inhibiting c-Myc-Max dimerization, allowing precise dissection of c-Myc-dependent pathways in cancer and stem cell models (CytC-Pigeon 2022).

Mechanism of Action of 10058-F4

10058-F4 functions as a selective, small-molecule inhibitor of the c-Myc-Max heterodimer. It binds to the c-Myc bHLH-Zip domain, preventing its association with Max. This disruption blocks c-Myc/Max DNA binding and downregulates c-Myc-dependent transcription, including genes vital for proliferation (e.g., TERT) and survival. Inhibition leads to decreased levels of c-Myc mRNA and protein, cell cycle arrest, and apoptosis via the mitochondrial (intrinsic) pathway. Specifically, 10058-F4 modulates Bcl-2 family proteins and triggers cytochrome C release from mitochondria, promoting caspase-dependent cell death. This mode of action is distinct from general transcription inhibitors, conferring pathway specificity and reduced off-target cytotoxicity (APExBIO A1169). Recent studies also show 10058-F4 induces repressive chromatin changes (H3K27me3) at the TERT promoter, further supporting its targeted mechanism (Kotian et al., 2024).

Evidence & Benchmarks

• 10058-F4 inhibits c-Myc-Max heterodimerization in vitro and in living cells, reducing c-Myc DNA binding and transcriptional activity (doi:10.1101/2024.09.16.613267).
• In human AML cell lines (HL-60, U937, NB-4), 10058-F4 induces apoptosis in a dose-dependent manner, with significant effects at 100 μM after 72 hours (CytC-Pigeon 2022).
• 10058-F4 treatment results in decreased c-Myc mRNA and protein levels and modulates Bcl-2 family proteins, promoting cytochrome C release (APExBIO).
• In vivo, intravenous 10058-F4 (dosing per published protocols) inhibits tumor growth in SCID mice bearing DU145/PC-3 prostate cancer xenografts, although efficacy varies by model (Angio-Amide 2023).
• In human pluripotent stem cells, 10058-F4 induces rapid accumulation of H3K27me3 at the TERT promoter and represses TERT transcription (doi:10.1101/2024.09.16.613267).

This article extends prior overviews such as 10058-F4: Advanced Strategies for Targeting c-Myc/Max by providing updated mechanistic insights into TERT regulation and benchmarking new chromatin effects, complementing established apoptosis and cancer models.

Applications, Limits & Misconceptions

10058-F4 is primarily used in cellular and molecular studies to dissect c-Myc-dependent transcription, apoptosis, and telomerase regulation. Its specificity enables studies in cancer biology, stem cell research, and drug discovery workflows, supporting robust apoptosis assays and pathway interrogation (Angio-Amide 2023). However, 10058-F4 is not a pan-transcription inhibitor and does not impact non-c-Myc-driven gene expression. Efficacy may vary between cell types and model organisms due to differences in c-Myc dependency and compound uptake.

Common Pitfalls or Misconceptions

• Not a pan-cancer agent: 10058-F4 is ineffective in cancers lacking c-Myc or Max dependency.
• Limited in vivo stability: The compound is not recommended for long-term solution storage; use freshly prepared solutions for each experiment (APExBIO).
• Solubility constraints: 10058-F4 is insoluble in water; use DMSO (≥24.9 mg/mL) or ethanol (≥2.64 mg/mL) for dissolution.
• Concentration-specific effects: Off-target toxicity may occur at high concentrations (>100 μM); verify dose-response in each model.
• Species differences: Regulatory effects noted in human cells may not fully translate to murine models due to divergent TERT promoter regulation (Kotian et al., 2024).

Workflow Integration & Parameters

To maximize reproducibility, dissolve 10058-F4 in DMSO (≥24.9 mg/mL) or ethanol (≥2.64 mg/mL) immediately before use. Store solid at -20°C and avoid repeated freeze-thaw cycles. For apoptosis assays, typical dosing ranges from 10–100 μM, with 72-hour incubation yielding robust c-Myc suppression in AML models. In vivo, administer via intravenous injection using published dosing schedules for SCID mouse xenografts. Always include appropriate vehicle controls and confirm c-Myc/Max target engagement by immunoblot or qPCR. For detailed protocol comparisons, see 10058-F4 for Robust c-Myc-Max Dimerization Inhibition, which focuses on best practices for apoptosis assay optimization, whereas this article updates molecular mechanisms and translational benchmarks.

Conclusion & Outlook

10058-F4, supplied by APExBIO (SKU A1169), is a gold-standard, selective c-Myc-Max dimerization inhibitor for apoptosis and cancer pathway research. Its robust activity in AML and prostate cancer models, coupled with emerging evidence of chromatin regulation at key loci like TERT, underscores its translational utility. Future directions include application in precision oncology, combinatorial screening, and mechanistic exploration of telomerase and chromatin remodeling in stem cell biology. For a broader translational perspective, see 10058-F4: Redefining c-Myc-Max Inhibition for Translation, which contrasts with this article by emphasizing DNA repair intersections, while the present review provides updated chromatin and apoptosis pathway insights.